Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: Expert panel recommendations

Basit Öğe Kaydı
dc.authorid0000-0002-2892-266X
dc.authorid0000-0001-8911-866X
dc.authorid0000-0003-1198-7894
dc.authorid0000-0003-0984-5694
dc.authorid0000-0002-5659-7809
dc.authorid0000-0002-8909-2102
dc.contributor.authorFouad, Yasser
dc.contributor.authorAlNaamani, Khalid M.
dc.contributor.authorAlawadi, Fatheya
dc.contributor.authorAl Hassani, Abdulla
dc.contributor.authorAlkhalidi, Nawal
dc.contributor.authorHotayt, Bilal
dc.contributor.authorAbaalkhail, Faisal
dc.contributor.authorRouabhia, Samir
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorEslam, Mohammed
dc.date.accessioned2026-07-24T12:38:13Z
dc.date.available2026-07-24T12:38:13Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction: Metabolic dysfunction–associated fatty liver disease (MAFLD) affects 25–30% of the global population, with the Middle East and North Africa (MENA) region showing some of the highest prevalence rates, reaching up to 40%. MAFLD is a common cause of cirrhosis and hepatocellular carcinoma and is a leading indication for liver transplantation in this region. Hitherto, there have been no specific pharmacotherapies for MAFLD. However, the recent conditional approval of resme tirom and semaglutide by the FDA for the treatment of non-cirrhotic moderate-to-advanced (fibrosis stages 2 or 3) metabolic-associated steatohepatitis (MASH) offers a much-needed therapeutic option for this largely underserved condition. Areas covered: An expert panel from the MENA region conducted a comprehensive literature search via PubMed and Google Scholar, focusing on clinical trials and international guidelines for resmetirom and semaglutide. This review identifies the target treatment population, proposes criteria for cessation of therapy, outlines monitoring protocols, and addresses regional knowledge gaps. Expert opinion: The approval of the first two drugs for MASH is a milestone. Access to and affordability of these therapies will be the crucial determinants of their actual adoption. Future efforts should consider individualized treatment pathways stratified by cost, regulatory status, and healthcare infra structure, while generating further regional evidence.
dc.identifier.citationFouad, Y., AlNaamani, K. M., Alawadi, F., Al Hassani, A., Alkhalidi, N., Hotayt, B., Abaalkhail, F., Rouabhia, S., Örmeci, N., & Eslam, M. (2026). Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: Expert panel recommendations. Expert Review of Endocrinology & Metabolism, pp. 1-9. https://doi.org/10.1080/17446651.2026.2698115
dc.identifier.doi10.1080/17446651.2026.2698115
dc.identifier.endpage9
dc.identifier.issn1744-6651
dc.identifier.issn1744-8417
dc.identifier.pmidPMID: 42397248
dc.identifier.scopus2-s2.0-105043943124
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.1080/17446651.2026.2698115
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1559
dc.identifier.wosWOS:001814534400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherESCI - Emerging Sources Citation Index
dc.institutionauthorÖrmeci, Necati
dc.institutionauthorid0000-0002-8909-2102
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Review of Endocrinology & Metabolism
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectResmetirom
dc.subjectSemaglutide
dc.subjectMASH
dc.subjectMAFLD
dc.subjectMENA
dc.subjectFibrosis
dc.titleResmetirom and semaglutide therapy for patients with MAFLD in the MENA region: Expert panel recommendations
dc.typeReview Article
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text.pdf
Boyut:
575.47 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu